ContraVir to Present at the Salomon Bio Investment & Leadership Conference

Nov 10, 2015, 09:00 ET from ContraVir Pharmaceuticals, Inc.

EDISON, N.J., Nov. 10, 2015 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Salomon Bio Investment & Leadership Conference 2015 to be held November 16, 2015 at the Convene Conference Center in New York, New York.

James Sapirstein, Chief Executive Officer, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. 

Event:


Salomon Bio Investment & Leadership Conference

Date: 


Monday, November 16, 2015

Time: 


11:30am (Eastern Time)

Location:


Convene Conference Center – 101 Park Avenue

A recording of ContraVir's presentation will be available after the conference.  To access the recording, please visit the investor relations section of the ContraVir website at www.contravir.com/ctrv.

About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir's lead clinical drug, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development.  In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study.  ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir, for the Hepatitis B virus (HBV).  CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects.  

For further information, please contact:

Tiberend Strategic Advisors, Inc. 

Tirth Patel (investors) 
tpatel@tiberend.com; (212) 375-2681

Claire Sojda (media)
csojda@tiberend.com; (212) 375-2686

SOURCE ContraVir Pharmaceuticals, Inc.